CanSino says vaccine demand down after China’s mass Covid infections
Chinese pharmaceutical group CanSino Biologics said demand for its Covid-19 vaccine was “dying down” in China after the abrupt end of the country’s tough zero-Covid policies, underscoring the challenges facing the sector in the largest remaining under-vaccinated market.
CanSino was in the middle of rolling out an inhaled version of a coronavirus vaccine when China shed lockdown restrictions in early December. The vaccine had received emergency approval, adding to the existing dozen domestic vaccines serving the Chinese population.
Beijing has refused to import BioNTech/Pfizer and Moderna’s mRNA jabs for its domestic population, despite research showing they provide higher level and more long-lasting protection than the widely used inactivated vaccines made by China’s Sinopharm and Sinovac.
This story originally appeared on: Financial Times - Author:Eleanor Olcott
